RxDoctor Payments Data

Jessica Chan, PA

Physician Assistant · Modesto, CANPI 1164992277

Payments from drug & device makers

$5,957in general payments, 2019–2025

Across 193 payments — averaging $30.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$832
  • Incyte Corporation$628
  • Sanofi$398
  • Regeneron Healthcare Solutions, Inc.$340
  • Dermavant Sciences, Inc.$306
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,39991%
  • Education$5589%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,957 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$413,738
Medicare patients
917
Services billed
7,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa13$260,304
Dupixent PenDupilumab23$101,099
OtezlaApremilast13$62,034
Fluorouracil479$34,707
Ketoconazole252$5,831
Tacrolimus19$3,682
Clobetasol Propionate93$3,447
Calcipotriene21$2,721
Metronidazole36$1,937
Fluocinonide16$1,548
Clindamycin Phosphate31$1,194
Fluocinolone AcetonideFluocinolone/Shower Cap12$969
Triamcinolone Acetonide87$905
Hydrocortisone66$694
Doxycycline Hyclate22$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$240$62,03413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →